Structure-Based Design of Potent Retinoid X Receptor α Agonists

Journal of Medicinal Chemistry

Volumn 47, Issue 8, 2004, Pages 2010-2029

  Haffner, Curt D ^a   Lenhard, James M ^a   Miller, Aaron B ^a   McDougald, Darryl L ^a   Dwornik, Kate ^a   Ittoop, Olivia R ^a   Gampe Jr , Robert T ^a   Xu, H Eric ^a,b   Blanchard, Steve ^a   Montana, Valerie G ^a   Consler, Tom G ^a   Bledsoe, Randy K ^a   Ayscue, Andrea ^a   Croom, Dallas ^a  

^a GLAXOSMITHKLINE   (United States)

^b VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [4 (5,5,8,8 TETRAMETHYL 5,6,7,8 TETRAHYDRO 2 NAPHTHALENYL)TETRAHYDRO 1 BENZOFURAN 2 YL] 2 PROPENOIC ACID; ACRYLIC ACID DERIVATIVE; ANTILIPEMIC AGENT; RETINOID X RECEPTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHIRAL CHROMATOGRAPHY; CONTROLLED STUDY; CRYSTALLIZATION; DOSE RESPONSE; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; GENETIC TRANSFECTION; GLUCOSE BLOOD LEVEL; LIPID METABOLISM; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; SPECIES COMPARISON; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ACRYLATES; ANIMALS; BENZOFURANS; BINDING SITES; CELL LINE; CRYSTALLOGRAPHY, X-RAY; DIABETES MELLITUS, TYPE 2; HAPLORHINI; HUMANS; HYPOGLYCEMIC AGENTS; LIGANDS; LIPIDS; MALE; MICE; MODELS, MOLECULAR; RADIOLIGAND ASSAY; RATS; RATS, ZUCKER; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 11144354615     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030565g     Document Type: Article

References (78)

1. For reviews, see (a) Orfanos, C. E.; Ehlert, R.; Gollnick, H. The Retinoids. A Review of Their Clinical Pharmacology and Therapeutic Use. Drugs 1987, 34, 459-503.
2. (b) Linney, E. Retinoic Acid Receptors: Transcription Factors Modulating Gene Regulation, Development, and Differentiation. Current Topics in Develomental Biology; Academic Press: Orlando, FL, 1992; pp 309-350.
3. (c) The Retinoids: Biology, Chemistry, and Medicine, 2nd ed.; Sporn, M. B., Roberts, A. B., Goodman, D. S., Eds.; Raven Press Ltd.: New York, 1994.
4. (d) Giguere, V. Retinoic Acid Receptors and Cellular Retinoid Binding Proteins: Complex Interplay in Retinoid Signaling. Endocr. Rev. 1994, 15, 61-79.
5. (e) Redfern, C. P. F. Molecular Mechanism of Retinoid Function. Adv. Organ Biol. 1997, 3, 35-77.
6. (f) Harvat, B.; Jetten, A. M. Growth Control by Retinoids: Regulation of Cell Cycle Progression and Apoptosis. Handbook Exp. Pharmacol. 1999, 139 (Retinoids), 239-276.
7. (a) Giguere, V.; Ong, E. S.; Segui, P.; Evans, R. M. Identification of a Receptor for the Morphogen Retinoic Acid. Nature 1987, 330, 624-629.
8. (b) Petrovich, M.; Brand, N. J.; Krust, A.; Chambon, P. A Human Retinoic Acid Receptor Which Belongs to the Family of Nuclear Receptors. Nature 1987, 330, 444-450.
9. (c) Allenby, G.; Bocquel, M.-T.; Saunders, M.; Kazmer, S.; Speck, J.; Rosenberger, M.; Lovey, A.; Kastner, P.; Grippo, J. F.; Chambon, P.; Levin, A. A. Retinoic Acid Receptors and Retinoid X Receptors: Interactions with Endogeneous Reetinoic Acids. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 30-34.
10. (a) Heyman, R. A.; Mangelsdorf, D. J.; Dyck, J. A.; Stein, R. B.; Eichele, G.; Evans, R. M.; Thaller, C. 9-cis-Retinoic Acid is a High Affinity Ligand for the Retinoid X Receptor. Cell 1992, 68, 397-406.
11. (b) Levin, A. A.; Sturzenbecker, L. J.; Kazmer, S.; Bosakowski, T.; Huselton, C.; Allenby, G.; Speck, J.; Kratzeisen, C.; Rosenberger, M.; Lovey, A.; Grippo, J. F. 9-cis-Retinoic Acid Stereoisomer Binds and Activates the Nuclear Receptor RXRα. Nature 1992, 355, 359-361.
12. 3H]-9-cis-Retinoic Acid and Its Application for Identifying Retinoids with Unusual Binding Properties. J. Med. Chem. 1994, 37, 408-414.
13. (a) Mangelsdorf, D. J.; Ong, E. S.; Dyck, J. A.; Evans, R. M. Nuclear Receptor That Identifies a Novel Retinoic Acid Response Pathway. Nature 1990, 345, 224-229.
14. (b) Mangelsdorf, D. J.; Borgmeyer, U.; Heyman, R. A.; Zhou, J. Y.; Ong, E. S.; Oro, A. E.; Kakizuka, A.; Evans, R. M. Characterization of Three RXR Genes That Mediate the Action of 9-cis-Retnoic Acid. Genes Dev. 1992, 6, 329-344.
15. For recent reviews, see (a) Dawson, M. I.; Zhang, X. Discovery and Design of Retinoic Acid Receptor and Retinoid X Receptor Class- and Subtype-Selective Synthetic Analogues of All-trans-Retinoic Acid and 9-cis-Retinoic Acid. Curr. Med. Chem. 2002, 9, 623-637.
16. (b) Kagechika, H. Novel Synthetic Retinoids and Separation of the Pleiotropic Retinoidal Activities. Curr. Med. Chem. 2002, 9, 591-608.
17. (a) Mangelsdorf, D. J.; Evans, R. M. The RXR Heterodimers and Orphan Receptors. Cell 1995, 83, 841-850.
18. (b) Rastinejad, F. Retinoid X Receptor and Its Partners in the Nuclear Receptor Family. Curr. Opin. Struct. Biol. 2001, 11, 33-38.
19. (a) Boehm, M. F.; Zhang, L.; Badea, B. A.; White, S. K.; Mais, D. E.; Berger, E.; Suto, C. M.; Glodman, M. E.; Heyman, R. A. Synthesis and Structure-Activity of Novel Retinoid X Receptor Selective Retinoids. J. Med. Chem. 1994, 37, 2930-2941.
20. (b) Boehm, M. F.; Zhang, L.; Zhi, L.; McClurg, M. R.; Berger, E.; Wagoner, M.; Mais, D. E.; Suto, C. M.; Davies, P. J. A.; Heyman, R. A.; Nadzan, A. M. Design and Synthesis of Potent Retinoid X Receptor Selective Ligands That Induce Apoptosis in Leukemia Cells. J. Med. Chem. 1995, 38, 3146-3155.
21. (c) Beard, R. L.; Colon, D. F.; Song, T. K.; Davies, P. J. A.; Kochhar, D. M.; Chandraratna, A. S. Synthesis and Structure-Activity Relationships of Retinoid X Receptor Selective Daryl Sulfide Analogues of Retinoic Acid. J. Med. Chem. 1996, 39, 3556-3563.
22. (d) Canan Koch, S. S.; Dardashti, L. J.; Hebert, J. J.; White, S. K.; Croston, G. E.; Flatten, K. S.; Heyman, R. A.; Nadzan, A. M. Identification of the First Retinoid X Receptor Homodimer Antagonist. J. Med. Chem. 1996, 39, 3229-3234.
23. (e) Vuligonda, V.; Lin, Y.; Chandraratna, A. S. Synthesis of Highly Potent RXR Specific Retinoids: The Use of a Cyclopropyl Group as a Double Bond Isostere. Bioorg. Med. Chem. Lett. 1996, 6, 213-218.
24. (f) Hibi, S.; Kikuchi, K.; Yoshimura, H.; Nagai, M.; Tai, K.; Hida, T. Syntheses and Structure-Activity Relationships of Novel Retinoid X Receptor Agonists. J. Med. Chem. 1998, 41, 3245-3252.
25. (f) Vuligonda, V.; Garst, M. E.; Chandraratna, A. S. Stereoselective Synthesis and Receptor Activity of Conformationally Defined Retinoid X Receptor Selective Ligands. Bioorg. Med. Chem. Lett. 1999, 9, 589-594.
26. (g) Canan Koch, S. S.; Dardashti, L. J.; Cesario, R. M.; Croston, G. E.; Boehm, M. F.; Heyman, R. A.; Nadzan, A. M. Synthesis of Retinoid X Receptor-Specific Ligands That Are Potent Inducers of Adipogenesis in 3T3-L1 Cells. J. Med. Chem. 1999, 42, 742-750.
27. (h) Ebisawa, M.; Umemiya, H.; Ohta, K.; Fukasawa, H.; Kawachi, E.; Christoffel, G.; Gronemeyer, H.; Tsuji, M.; Hashimoto, Y.; Shudo, K.; Kagechika, H. Chem. Pharm. Bull. 1999, 47, 1778-1786.
28. (i) Dawson, M. I.; Hobbs, P. D.; Jong, L.; Xiao, D.; Chao, W.; Pan, C.; Zhang, X. sp2-Bridged Diaryl Retinoids: Effects of Bridge-Region Substitution on Retinoid X Receptor (RXR) Selectivity. Bioorg. Med. Chem. Lett. 2000, 10, 1307-1310.
29. (j) Takahashi, B.; Ohta, K.; Kawachi, E.; Fukasawa, H.; Hashimoto, Y.; Kagechika, H. Novel Retinoid X Receptor Antagonists: Specific Inhibition of Retinoid Synergism in RXR-RAR Heterodimer Actions. J. Med. Chem. 2002, 45, 3327-3330.
30. (k) Faul, M. M.; Grese, T. A. Selective RXR Modulators for the Treatment of Type II Diabetes. Curr. Opin. Drug Discovery Dev. 2002, 5, 974-985.
31. (l) Farmer, L. J.; Zhi, L.; Jeong, S.; Lamph, W. W.; Osburn, D. L.; Croston, G.; Flatten, K. S.; Heyman, R. A.; Nadzan, A. M. Retinoic Acid Receptor Ligands Based on the 6-Cyclopropyl-2,4-hexadienoic Acid. Bioorg. Med. Chem. Lett. 2003, 13, 261-264.
32. (m) Bell, M. G.; Grese, T. A.; Gernert, D. L.; Yumbie, N. P.; Boehm, M. F.; Michellys, P.-Y.; Ardecky, R. J.; Mapes, C. M.; Chen, J.-H. Fluorinated Trienes and Their Use as RXR Modulators. WO 02/072528, 2002.
33. (n) Gardinier, K. M.; Gernert, D. L.; Grese, T. A.; Neel, D. A.; Mapes, C. M.; Michellys, P.-Y.; Boehm, M. F. Retinoid X Receptor Modulators. WO 02/071827, 2002.
34. (o) Grese, T. A.; Gardinier, K. M.; Boehm, M. F. (Pyridinyl and Pyrimidyl)Trienoic Acid Derivatives as Retinoid X Receptor Modulators. WO 03/007950, 2003.
35. (p) Michellys, P. Y.; Ardecky, R. J.; Chen, J. H.; Crombie, D. L.; Etgen, G. J.; Faul, M. M.; Faulkner, A. L.; Grese, T. A.; Heyman, R. A.; Karanewsky, D. S.; Klausing, K.; Leibowitz, M. D.; Liu, S.; Mais, D. A.; Mapes, C. M.; Marschke, K. B.; Reifel-Miller, A.; Ogilive, K. M.; Rungta, D.; Thompson, A. W. Novel (2E,4E,6Z)-7-(2-Alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-tienoic Acid Retinoid X Receptor Modulators Are Active in Models of Type 2 Diabetes. J. Med. Chem. 2003, 46, 2683-2696.
36. (q) Michellys, P.-Y.; Ardecky, R. J.; Chen, J.-H.; D'Arrigo, J.; Grese, T. A.; Karanewsky, D. S.; Leibowitz, M. D.; Liu, S.; Mais, D. A.; Mapes, C. M.; Montrose-Rafizadeh, C.; Oglive, K. M.; Reifel-Miller, A.; Rungta, D.; Thompson, A. W.; Tyhonas, J. S.; Boehm, M. F. Design, Synthesis, and Structure-Activity Relationship Studies of Novel 6,7-Locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic Acids. J. Med. Chem. 2003, 46, 4087-4103.
37. (a) Schulman, D.; Crombie, R. P.; Bissonnette, R. P.; Cesario, R.; Roegner, K.; Shao, G.; Heyman, R. A. RXR Specific Agonists and Modulators: A New Retinoid Pharmacolgy. Handbook Exp. Pharmacol. 1999, 139 (Retinoids), 215-235.
38. (b) Cesario, R. M.; Klausing, K.; Razzaghi, H.; Crombie, D.; Rungta, D.; Heyman, R. A.; Lala, D. S. The Rexinoid LG100754 is a Novel RXR:PPARγ Agonist and Decreases Glucose Levels In Vivo. Mol. Endocrinol. 2001, 15, 1360-1369.
39. Lenhard, J. M.; Croom, D. K.; Weiel, J. E.; Winegar, D. A. HIV Protease Inhibitors Stimulate Hepatic Triglyceride Syntheis. Arterioscler., Thromb., Vasc. Biol. 2000, 20, 2625-2629.
40. Lenhard, J. M. PPARγ/RXR as a Therapeutic Target for Diabetes. Receptors Channels 2001, 7, 249-258.
41. (a) Mukherjee, R.; Davies, P. J. A.; Crombie, D. L.; Bischoff, E. D.; Cesario, R. M.; Jow, L.; Hamann, L. G.; Boehm, M. F.; Mondon, C. E.; Nadzan, A. M.; Paterniti, J. R., Jr.; Heyman, R. A. Sensitization of Diabetic and Obese Mice to Insulin by Retinoid X Receptor Agonists. Nature 1997, 386, 407-410.
42. (b) Lenhard, J. M.; Lancaster, M. E.; Paulik, M. A.; Weiel, J. E.; Binz, J. G.; Sundseth, S. S.; Gaskill, B. A.; Lightfoot, R. M.; Brown, H. R. The RXR Agonist LG100268 Causes Hepatomegaly, Improves Glycaemic Control and Decreases Cardivascular Risk and Cachexia in Diabetic Mice Suffering From Pancreatic Beta-Cell Dysfunction. Diabetologia 1999, 42, 545-554.
43. (c) Paterniti, J. R., Jr.; Mukherjee, R. The PPAR/RXR Heterodimer: Therapeutic Target for Insulin Resistance and Obesity. In Nutrition, Genetics and Obesity: Pennington Center Nutrition Series; Louisiana State University Press: LA, 1999; Vol. 9, pp 477-492.
44. (d) Liu, Y. L.; Sennit, M. V.; Hislop, D. C.; Crombie, D. L.; Heyman, R. A.; Cawthorne, M. A. Retinoid X Receptor Agonists Have Anti-obesity Effects and Improve Insulin Sensitivity in Zucker fa/fa Rats. Int. J. Obes. Relat. Metab. Disord. 2000, 24, 997-1004.
45. (e) Cha, B. S.; Ciaraldi, T. P.; Carter, L.; Nikoulina, S. E.; Mudaliar, S.; Mukherjee, R.; Paterniti, J. R., Jr.; Henry, R. R. Peroxisome Proliferator-Activated (PPAR)γ and retinoid X Receptor (RXR) Agonists Have Complementary Effects on Glucose and Lipid Metabolism in Human Skeletal Muscle. Diabetologia 2001, 44, 444-452.
46. (f) Cesario, R. M.; Klausing, K.; Razzaghi, H.; Crombie, D.; Rungta, D.; Heyman, R. A.; Lala, D. S. The Rexinoid LG100754 Is a Novel RXR:PPARγ Agonist and Decreases Glucose Levels in Vivo. Mol. Endocrinol. 2001, 15, 1360-1369.
47. Bourguet, W. R. M.; Chambon, P.; Gronemeyer, H.; Moras, D. Crystal Structure of the Ligand Binding Domain of the Human Nuclear Receptor RXRα. Nature 1995, 375, 377-382.
48. Gampe, R. T., Jr.; Montana, V. G.; Lambert, M. H.; Miller, A. B.; Bledsoe, R. K.; Milburn, M. V.; Kliewer, S. A.; Willson, T. M.; Xu, H. E. Asymmetry in the PPARγ/RXRα Crystal Structure Reveals the Molecular Basis of Heterodimerization Amoung Nuclear Receptors. Mol. Cell 2000, 5, 545-555.
49. (a) Compound 23: Dawson, M. I.; Jong, L.; Hobbs, P. D.; Cameron, J. F.; Chao, W.; Pfahl, M.; Lee, M.-O.; Shroot, B.; Pfahl, M. Conformational Effects on Retinoid Receptor Selectivity. 2. Effects of Retinoid Bridging Group on Retinoid X Receptor Activity and Selectivity. J. Med. Chem. 1995, 38, 3368-3383.
50. (b) Compound 24: Qing, F.-L.; Fan, J.; Sun, H.-B.; Yue, X.-J. First Synthesis of ortho-Trifluoromethylated Aryl Triflates. J. Chem. Soc., Perkin Trans. 1 1997, 20, 3053-3057.
51. (c) Compound 25: Canan-Koch, S.; Hwang, C. K.; Boehm, M. F.; Badea, B. A.; Dardashti, L. J.; Zhang, L.; Nadzan, A. M.; Heyman, R. A.; Mukherjee, R.; Lala, D. S.; Farmer, L. J. Dimer-Selective RXR Modulators and Methods For Their Use. WO 9712853, 1997.
52. Wood, T. F.; Evans, W. F. Method and Composition for Controlling Weeds With Acylated Tetrahydronaphthalene. U.S. Patent 3499751, 1970.
53. Lee, Y. R.; Suk, Y. Rhodium(II)-Catalyzed Cycloaddition of Cyclic Diazodicarbonyl Compounds With Nitriles. Synthesis of Tetrahydrobenzoxazoles, Tetrahydrobenzofurans, and Tetrahydrobenzodioxoles. Heterocycles 1998, 48, 875-883.
54. Schneider, C. S.; Pook, K. H. Acid-Catalyzed Cyclization of 1-Aryl-2-thienylmethyl and 1-Aryl-2-furfurylaminoethanols via Spiro Intermediates. J. Chem. Soc., Perkin Trans. 1 1986, 877-883.
55. Nichols, J. S.; Parks, D. J.; Consler, T. G.; Blanchard, S. G. Development of a Scintillation Proximity Assay for Peroxisome Proliferator-Activated Receptor γ Ligand Binding Domain. Anal. Biochem. 1998, 257, 112-119.
56. Paulik, M. A.; Lenhard, J. M. Thiazolidinediones Inhibit Alkaline Phosphatase While Increasing Expression of Uncoupling Protein and Deiodinase and Increasing Mitochondrial Mass in C3H10T1/2 Cells. Cell Tissue Res. 1997, 290, 79-87.
57. Henke, B. R.; Blanchard, S. G.; Brackeen, M. F.; Brown, K. K.; Cobb, J. E.; Collins, J. L.; Harrington, W. W., Jr.; Hashim, M. A.; Hull-Ryde, E. A.; Kaldor, I.; Kliewer, S. A.; Lake, D. H.; Leesnitzer, L. M.; Lehmann, J. M.; Lenhard, J. M.; Orband-Miller, L. A.; Miller, J. F.; Mook, R. A.; Noble, S. A.; Oliver, W.; Parks, D. J.; Plunket, K. D.; Szewczyk, J. R.; Willson, T. M. N-(2-Benzoylphenyl)-L-tyrosine PPARγ. 1. Discovery of a Novel Series of Potent Antihyperglycemic and Antihyperlipidemic Agents. J. Med. Chem. 1998, 41, 5020-5036.
58. Freedman, L. P. Increasing the Complexity of Coactivation in Nuclear Receptor Signaling. Cell 1999, 97, 5-8.
59. (a) Bourguet, W.; Ruff, M.; Chambon, P.; Gronmeyer, H.; Moras, D. Crystal Structure of the Ligand-Binding Domain of the Human Nuclear Receptor RXRα. Nature 1995, 375, 377-382.
60. (b) Renaud, J.-P.; Rochel, N.; Ruff, M.; Vivat, V.; Chambon, P.; Moras, D. Crystal Structure of the PPARγ Ligand Binding Domain Bound to All-Trans Retinoic Acid. Nature 1995, 378, 681-689.
61. (c) Nolte, R. T.; Wisely, G. B.; Westin, S.; Cobb, J. E.; Lambert, M. H. ; Kurokawa, R.; Rosenfeld, M. G.; Willson, T. M.; Glass, C. K.; Milburn, M. V. Ligand Binding and Co-activator Assembly of the Peroxisome Proliferator-Activated Receptor-γ. Nature 1998, 395, 137-143.
62. (d) Xu, H. E.; Lambert, M. H.; Montana, V. G.; Parks, D. J.; Blanchard, S. G.; Brown, P. J.; Sternbach, D. D.; Lehmann, J. M.; Wisely, G. B.; Willson, T. M.; Kliewer, S. A.; Milburn, M. V. Molecular Recognition of Fatty Acids by Peroxisome Proliferator-Activated Receptors. Mol. Cell 1999, 3, 397-403.
63. (a) Heyman, R. A.; Mangelsdorf, D. J.; Dyck, J. A.; Stein, R.; Eichele, G.; Evans, R. M.; Thaller, C. 9-Cis Retinoic Acid is a High Affinity Ligand for the Retinoid X Receptor. Cell 1992, 68, 397-406.
64. (b) Levin, A. A.; Sturzenbecker, L. J.; Kazmer, S.; Bosakowski, T.; Huselton, C.; Allenby, G.; Speck, J.; Kratzeisen, C.; Rosenberger, M.; Lovey, A. 9-Cis Retinoic Acid Stereoisomer Binds and Activates the Nuclear Receptor RXRα. Nature 1992, 355, 359-361.
65. Standeven, A. M.; Escobar, M.; Beard, R. L.; Yuan, Y.-D.; Chandraratna, R. A. S. Mitogenic Effect of Retinoid X Receptor Agonists in Rat Liver. Biochem. Pharm. 1997, 54, 517-524.
66. (a) Sherman, S. I.; Gopal, J.; Haugen, B. R.; Chiu, A. C.; Whaley, K.; Nowlakha, P.; Duvic, M. Central Hypothyroidism Associated With Retinoid X Receptor-Selective Ligands. N. Engl. J. Med. 1999, 340, 1075-1079.
67. (b) Liu, S.; Ogilive, K. M.; Klausing, K.; Lawson, M. A.; Jolley, D.; Li, D.; Bilakovics, J.; Pascul, B.; Hein, N.; Urcan, M.; Leibowitz, M. D. Mechanism of Selective Retinoid X Receptor Agonist-Induced Hypothyroidism in the Rat. Endocrinology 2002, 143, 2880-2885.
68. Vu-Dac, N.; Gervois, P.; Torra, I. P.; Fruchart, J. C.; Kosykh, V.; Kooistra, T.; Princen, H. M.; Dallongeville, J.; Staels, B. Retinoids Increase Human Apo C-III Expression at the Transcriptional Level Via the Retinoid X Receptor. Contribution to the Hypertriglyceridemic Action of Retinoids. J. Clin. Invest. 1998, 102, 625-632.
69. Willson, T. M.; Cobb, J. E.; Cowan, D. J.; Wiethe, R. W.; Correa, I. D.; Prakash, S. R.; Beck, K. D.; Moore, L. B.; Kliewer, S. A.; Lehmann, J. M. The Structure-Activity Relationship Between Peroxisome Proliferator-Activated Receptor γ Agonsim and the Antihyperglycemic Activity of Thiazolidinediones. J. Med. Chem. 1996, 39, 665-668.
70. Lehmann, J. M.; Moore, L. B.; Smith Oliver, T. A.; Wilkinson, W. O.; Willson, T. M.; Kliewer, S. A. An Antidiabetic Thiazolidinedione is a High Affinity Ligand for Peroxisome Proliferator-Activated Receptor γ (PPARγ). J. Biol. Chem. 1995, 270, 12953-12956.
71. Mangelsdorf, D. J.; Umesono, K.; Kliewer, S. A.; Borgmeyer, U.; Ong, E. S.; Evans, R. M. A Direct Repeat in the Cellular Retinol-Binding protein Type II Gene Confers Differential Regulation by RXR and RAR. Cell 1991, 66, 555-561.
72. InsightII, Discover, CNX, and Quanta are available from Accelrys Inc., 9685.
73. Lambert, M. H. Docking Conformationally Flexible Molexules into Protein Binding Sites. In Practical Aplication of Computer-Aided Drug Design; Charifson, P. S., Ed.; Marcel-Dekker: New York, 1997; pp 243-303.
74. Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. Methods Enzymol. 1997, 276, 307-326.
75. (a) Navaza, J. AmoRe: An Automated Package for Molecular Replacement. Acta Crystallogr. 1994, A50, 157-163.
76. (b) Collaborative Computational Project Number 4. Acta Crystallogr. 1994, D50, 760-776.
77. Brunger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J. S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Crystallography and NMR System: A New Software Suite for Macromolecular Structure Determination. Acta Crystallogr. D 1998, 54, 905-921.
78. Figures 3B, 4A,D, and 5 were made using PYMOL (www.pymol.org). Figure 3A was made using Insight and Figure 4B was made using Quanta.